利格列汀应用于牙髓血运重建治疗的安全性探索

Safety of linagliptin application in the pulp revascularization

目的:研究DPP-4抑制剂利格列汀对大鼠牙髓血运重建治疗中血糖与体重的影响。方法:将18只SD大鼠随机分为3组,每组6只。实验组:下颌第一磨牙行牙髓血运重建术并灌胃利格列汀;对照组:下颌第一磨牙行牙髓血运重建术并灌胃羧甲基纤维素钠;空白组:下颌第一磨牙不作处理并灌胃羧甲基纤维素钠。在实验前及灌胃后7d、14d、21d、28d检测大鼠空腹血糖及体重。结果:在实验前和灌胃7d、14d、21d、28d后3组大鼠空腹血糖值及体重差值比较,差异均无统计学意义(均P>0.05)。结论:DPP-4抑制剂利格列汀对于牙髓血运重建中大鼠的血糖与体重无明显影响。

Objective: To investigate the effect of DPP-4 inhibitor,linagliptin on the blood glucose and body weight during pulp revascularization inrats. Methods: 18 SD rats were randomly divided into three groups(n=6).Experimental group:mandibular first molars with pulp revascularization and oral gavage linagliptin.Control group:mandibular first molars with pulp revascularization and oral gavage sodium carboxymethylcellulose.Blank control group:normal molars and oral gavage sodium carboxymethylcellulose.The fasting blood sugar and body weight were detected before experiment and 7,14,21 and 28 days after oral gavage. Results: There was no significant difference in body weight and fasting blood glucose among the three groups before experiment and 7,14,21 and 28 days after oral gavage(P >0.05). Conclusion: DPP-4 inhibitor linagliptin had no significant effect on blood glucose or body weight during pulp revascularization in rats.